Precision Synthesis: Oligonucleotide Purification Market Set to Grow from USD 282 Million to USD 400 Million by 2032 Global Leading Market Research Publisher QYResearch announces the release of its latest report "Oligonucleotide Purification - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oligonucleotide Purification market, including market size, share, demand, industry development status, and forecasts for the next few years. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6069937/oligonucleotide-purification Market Analysis: Steady Growth in Nucleic Acid Manufacturing According to the latest market analysis, the global Oligonucleotide Purification market was valued at approximately USD 282 million in 2025 and is projected to reach USD 400 million by 2032, growing at a steady CAGR of 5.2% from 2026 to 2032. This consistent market growth reflects the accelerating demand for high-purity oligonucleotides driven by the rapid expansion of gene therapy, antisense oligonucleotide (ASO) therapeutics, mRNA vaccines, molecular diagnostics, and next-generation sequencing (NGS), where product purity directly impacts assay performance, therapeutic efficacy, and patient safety. For biopharmaceutical manufacturing executives, oligonucleotide therapy developers, molecular diagnostics companies, and contract research organization (CRO) investors, this market research signals a stable growth segment where purification scalability, yield, and regulatory compliance are critical success factors. Product Definition: Removing Synthesis Impurities for High-Purity Oligos Oligonucleotide purification service refers to the purification of synthesized oligonucleotides using high-performance liquid chromatography (HPLC), gel electrophoresis, or other chromatographic techniques to remove truncated sequences (failed synthesis products where chemical coupling steps were inefficient, resulting in deletion sequences (n-1, n-2, etc.)), residual reagents (phosphoramidites, activators, deblocking agents (trichloroacetic acid, dichloroacetic acid)), protecting groups (dimethoxytrityl (DMT) groups remain attached after synthesis until deprotected), and other impurities produced during the solid-phase oligonucleotide synthesis process (spike impurities (depurination, alkylation, oxidation products), salts and solvents from cleavage and deprotection steps). The purification process ensures the high purity and stability of the final product (removal of truncated sequences is essential for therapeutic oligonucleotides where impurities could cause off-target effects or reduce efficacy). This service is essential for molecular diagnostics (PCR primers must have high purity (typically >90-95 percent) to avoid non-specific amplification, incorrect test results (false positives/negatives). Probe sequences (TaqMan, molecular beacons, FRET probes) require high purity for consistent fluorescence signal and accurate quantification), gene therapy (single-stranded DNA (ssDNA) or RNA oligonucleotides for gene editing (CRISPR guides), antisense oligonucleotides (ASOs) require high purity for regulatory approval and patient safety), PCR and sequencing (NGS library preparation (adapters, barcodes, primers) require high purity to avoid sequencing errors and sample misassignment; Sanger sequencing primers require high purity for accurate base calling), and other applications that require high precision and consistency. In recent years, with the rapid development of genomics, personalized medicine, and biopharmaceuticals, the demand for high-quality oligonucleotides has continued to increase, driving the continued growth of the purification service market. Key Industry Drivers and Market Dynamics Industry Trend 1: RNA Therapeutics and Antisense Oligonucleotides (ASOs) The most significant driver of oligonucleotide purification demand is the growth of RNA therapeutics and antisense oligonucleotides (ASOs). According to the Oligonucleotide Therapeutics Society (OTS) 2025 Pipeline Report, there are over 100 oligonucleotide therapeutics in clinical development (including ASOs, small interfering RNA (siRNA), microRNA (miRNA) mimics/inhibitors, aptamers). FDA-approved oligonucleotide drugs include ASOs: fomivirsen (CMV retinitis, withdrawn), mipomersen (homozygous familial hypercholesterolemia), eteplirsen (Duchenne muscular dystrophy, exon 51 skipping), nusinersen (Spinraza, spinal muscular atrophy), inotersen (familial amyloid polyneuropathy), golodirsen (DMD, exon 53 skipping), viltolarsen (DMD, exon 53 skipping); siRNAs: patisiran (Onpattro, hereditary transthyretin-mediated amyloidosis), givosiran (Givlaari, acute hepatic porphyria), lumasiran (Oxlumo, primary hyperoxaluria type 1), inclisiran (Leqvio, hypercholesterolemia), vutrisiran (Amvuttra, ATTR amyloidosis); aptamers: pegaptanib (Macugen, age-related macular degeneration). Large-scale manufacturing of therapeutic oligonucleotides requires industrial-scale purification: HPLC columns for process-scale purification (hundreds of grams to kilograms per year). Purification must meet regulatory requirements (ICH Q7 (GMP for active pharmaceutical ingredients), FDA guidance for oligonucleotide therapeutics (draft guidance, 2024)). Purity requirements are higher for therapeutic oligonucleotides (>95-99 percent full-length product). Impurity profiling is required (identification and quantification of n-1, n-2, and other deletion sequences, oxidation, deamination, depurination, adducts). This drives demand for high-resolution purification methods and analytical support. Industry Trend 2: mRNA Vaccines and Therapeutics The success of mRNA vaccines for COVID-19 (Pfizer/BioNTech Comirnaty, Moderna Spikevax) has accelerated development of mRNA therapeutics for other infectious diseases (RSV, influenza, HIV, Zika, malaria), cancer immunotherapies (personalized neo-antigen vaccines, checkpoint modulators), protein replacement therapies (mRNA encoding missing enzymes). mRNA synthesis requires DNA templates (plasmids or linear DNA) (oligonucleotide purification needed for DNA template synthesis). mRNA itself is produced by in vitro transcription (IVT). IVT requires NTPs (nucleotides), cap analogs, RNA polymerase, and DNA template. However, purification of IVT mRNA is typically done by different methods (reverse-phase or ion pair HPLC, affinity chromatography, TFF (tangential flow filtration)), not the same as oligonucleotide purification service (which is for shorter synthetic oligos (<200 nt), not for mRNA (>1000 nt)). However, the expanded ecosystem of RNA therapeutics has increased demand for high-purity synthetic oligonucleotides used in manufacturing process (primers for plasmid production, NGS QC of templates, probes for in-process testing). This indirect effect has grown the overall oligonucleotide market, benefiting purification services. Industry Trend 3: Technology Segmentation – HPLC Dominates The market segments by purification technology into Reversed-Phase Cartridge Purification (approximately 20-25 percent of market share, entry-level), HPLC Oligo Purification (approximately 55-60 percent, largest segment), PAGE Oligo Purification (approximately 10-15 percent, specialized), and Other (5-10 percent – ion exchange HPLC, size exclusion chromatography, etc.). HPLC (High-Performance Liquid Chromatography) is the dominant method for high-purity oligos (research-grade and therapeutic-grade). The most common mode is reversed-phase HPLC (RP-HPLC) using C18 (octadecyl) or C8 columns. RP-HPLC separates by hydrophobicity (full-length product has DMT group protecting 5' terminus; DMT group is hydrophobic, causing full-length oligo to retain longer on column. Truncated sequences lack DMT group, elute earlier). RP-HPLC can achieve >95 percent purity for 20-60 mers. It is scalable from microgram to gram quantities. It can be automated (automated HPLC systems for high-throughput purification). RP-HPLC is the standard for therapeutic oligonucleotide purification (process-scale HPLC uses large columns (up to 30 cm diameter), high flow rates). Ion pair (IP)-RP-HPLC uses ion-pairing reagents (triethylammonium acetate (TEAA), hexafluoro-2-propanol (HFIP)) to improve separation of oligonucleotides (independent of DMT group). IP-RP-HPLC can purify sequences where DMT-on purification is not sufficient (for long oligos >60 nt, for post-synthesis modifications where DMT is not retained). Ion exchange HPLC (IEX) separates by charge (negatively charged phosphate backbone; longer sequences have higher charge). IEX is less common for oligo purification but used for some applications (DNA duplexes, larger RNA). HPLC is the largest segment because it is the most versatile, scalable, and regulatory-accepted method. Reversed-Phase Cartridge Purification uses disposable cartridges containing reversed-phase media (C18 resin). The crude synthesis product is loaded; DMT-on full-length binds; truncated sequences elute. DMT is removed (detritylation) and product eluted. Advantages include lower equipment cost (no HPLC system required; simple syringe or vacuum manifold), lower per-sample cost for small scale (48-96 samples in parallel), and rapid (5-10 minutes per sample). Disadvantages include lower purity (typically 80-90 percent vs. >95 percent for HPLC), limited scalability (not suitable for >milligram scale), manual process (less automation). Cartridge purification is used for research-scale oligos (10-200 nmol synthesis scale) where >90 percent purity is sufficient (e.g., standard PCR primers, Sanger sequencing primers). It is not used for therapeutic oligos or high-sensitivity applications (NGS library prep for clinical diagnostics). It is the most common purification method for commercial oligo suppliers for standard primers. Annual cartridge volumes are high, but price per oligo is low. PAGE (Polyacrylamide Gel Electrophoresis) Purification separates oligonucleotides by size on a denaturing polyacrylamide gel. Full-length product is excised from gel, eluted, and desalted. Advantages include highest resolution for separating full-length from n-1 and other deletion sequences; can separate sequences that are difficult to separate by HPLC (due to similar hydrophobicity or strong secondary structure). It is suitable for long oligos (>80-100 nt) where HPLC yield is low. PAGE is used for specialized applications (long oligos for gene assembly (gBlocks, gene fragments), modified oligos where modifications affect hydrophobicity, diagnostic oligos requiring absolute purity). Disadvantages include manual, labor-intensive process, low throughput (hours per sample), low yield (50-75 percent recovery after gel extraction), and not scalable to >micromole scale. PAGE has declining share as HPLC methods improve and as demand for high-throughput purification increases. Industry Trend 4: Market Segmentation – Scientific Research vs. Pharmaceutical Production By application, the market segments into Scientific Research (approximately 70-75 percent of market share, largest segment) and Pharmaceutical Production (approximately 25-30 percent, fastest-growing at 8-9 percent CAGR). Scientific Research includes academic and government research labs (university core facilities, individual research groups) and institutional research (pharmaceutical company research groups, biotech R&D, not for clinical/commercial supply). This segment uses a mix of cartridge purification (for standard primers) and HPLC (for high-purity needs). Commercial oligo suppliers (Integrated DNA Technologies (IDT), now part of Danaher; Eurofins Genomics (Eurogentec); GenScript; Thermo Fisher (custom oligo synthesis); Azenta (GENEWIZ); Biosearch Technologies; Oligo Factory; Tsingke Biotech (China); GenScript (Nanjing, China); SUZHOU NANOMICRO TECHNOLOGY (China); Asymchem (China, primarily manufacturing, but may have purification services); GentleGen (China, synthetic biology)); many also provide purification services as part of oligo synthesis. The research segment is price-sensitive and values fast turnaround (purification time adds to oligo delivery time). Pharmaceutical Production includes GMP-grade oligonucleotides for clinical trials and commercial therapeutic products (bulk API (active pharmaceutical ingredient) for ASO and siRNA drugs). This segment requires process-scale HPLC, rigorous quality control, and full documentation for regulatory submission. The pharmaceutical segment is the growth driver (double-digit growth, albeit from smaller base). Many large pharma companies have internal oligonucleotide manufacturing; others outsource to CDMOs (Agilent (through manufacturing division), Thermo Fisher (Patheon), Cytiva (part of Danaher, oligo synthesis and purification equipment/services), Asymchem (China-based CDMO)). This segment is less price-sensitive and values regulatory compliance, batch-to-batch consistency, and supply chain security. Exclusive Analyst Insight: Commercial Oligo Suppliers From my industry analysis perspective, the commercial oligo synthesis market (including purification) is served by a combination of global suppliers and regional players. Leading global suppliers include Integrated DNA Technologies (IDT) (now part of Danaher, US, IDT is the market leader in custom oligos for research; comprehensive purification offerings). Thermo Fisher Scientific (custom oligo synthesis through its GeneArt, Invitrogen brands). Azenta Life Science (formerly GENEWIZ, oligo synthesis and purification). Eurogentec (Belgium, part of Kaneka Corporation (Japan), oligo synthesis, purification, and GMP manufacturing). GenScript (China/US, oligo synthesis and molecular biology services). Biosearch Technologies (US, part of LGC (UK), oligo synthesis, purification, specialty modifications). Other players include Oligo Factory (US, specialized in long, high-purity oligos), IntegrateRNA (US, RNA synthesis and purification), Cytiva (supplies purification instruments, columns, and consumables, rather than service). Agilent (supplies instruments (HPLC, LC-MS) and columns; also offers oligonucleotide purification services through its pharmaceutical manufacturing division? Limited). Chinese regional players (SUZHOU NANOMICRO TECHNOLOGY, Beijing Tsingke Biotech, GentleGen) serve the growing Chinese research market; may expand internationally as they develop GMP capabilities. In conclusion, the oligonucleotide purification market offers steady, gene-therapy-driven growth with a projected USD 400 million market size by 2032. Success factors for service providers include purification scalability (from nmole to kg quantities), purity levels (research vs. therapeutic requirements), and regulatory compliance for GMP manufacturing. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp